Pharmacol. 24, 551-3, 1987) that when histamine H2 -receptor antagonists are co-administered with antacids, especially antacids with high acid-neutralising capacity, a substantial reduction in the plasma bioavailability of the histamine H2 -receptor antagonist is frequently observed.